The Dose

Welcome to The Dose, which tackles the finances behind local health care and life sciences and points to the most interesting national analysis. Your host is J.K. Wall.

More patients help drug firms pass 'valley of death'

In spite of the beaucoup bucks in the pharma sector, patients, along with their families and committed advocates, are turning out to be better sources of funding for early stage companies because they tolerate risk better than drug companies and investors.
Read More

Most drug money in Indiana funds research. Is that good?

With federal research funding declining, drug companies are taking a larger role funding the medical research happening at IU and universities around the country. That's not the same thing as paying to market drugs, but it's hardly without controversy.
Read More

Indy patients love their doctors

Indianapolis ranked fifth highest among the nation’s largest cities for the most positive reviews of physicians. On a five-point Patient Happiness Index, the average review by patients scored Indianapolis physicians at a 4.05. San Francisco physicians topped the list.
Read More

Doctors' drug money

Indiana physicians and research organizations reaped more than $25 million in payments from 15 pharmaceutical firms in 2012, according to the most recent data made available by the not-for-profit group ProPublica. Lilly was the biggest spender and the IU medical school was the biggest recipient.
Read More

Five things I learned from the Medicare doctor payments

From this week's historic data dump, I learned who the top 20 recipients of Medicare payments are in Indianapolis (hint: mostly labs, ambulances and eye surgeons). But the real takeaway is that meaningful price information about doctors is still a long way away.
Read More

Lilly shares hit all-time high for the John Lechleiter era

Court win last week in a patent challenge to lung cancer drug Alimta pushed Lilly shares higher than they've ever been since April 2007. Since then, the company’s pipeline has produced more misfires than the villains in a James Bond movie
Read More

Life sciences jobs pack 2-for-1 punch

While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
Read More

No one likes Obamacare

Obamacare has officially arrived, but both conservatives and liberals are calling it awful. That means the real debate over health reform is just beginning.
Read More

Health care has priced itself out of its own market

It’s no secret the growth of the U.S. economy slowed in the 2000s after the go-go decade preceding it. But the U.S. health care system—hospitals, doctors, drug companies, device makers and health insurers—apparently didn’t get that memo.
Read More

The bill for Hoosiers’ excess health care spending: About $5 billion per year

Hoosiers' poor health, combined with an aggressive health care system and an uncompetitive health insurance sector, means Hoosiers, in spite of the fact that they earn just 86 cents for every dollar earned by the average American, are spending nearly $1.13 on health care for every dollar spent by Americans.
Read More